NASDAQ · ACRV
Acrivon Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ACRV: Nov 12, 2026
Acrivon Therapeutics, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.45. The reported EPS for the same quarter last year was $-0.47.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.45 | $-0.43 | $-0.48 | 3 |
| Dec 2026 | $-0.48 | $-0.46 | $-0.53 | 3 |
| Mar 2027 | $-0.48 | $-0.48 | $-0.48 | 1 |
| Jun 2027 | $-0.51 | $-0.51 | $-0.51 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · NASDAQ.com · Fintel- Zacks · Sep 15, 12:00 PM EDTWhat Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy StockAcrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks · Sep 3, 9:55 AM EDTAcrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
- Zacks · Aug 24, 12:00 PM EDTHere's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to BuyDoes Acrivon Therapeutics, Inc. (ACRV) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks · Mar 3, 12:00 PM ESTAcrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's WhyAcrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- RTTNews · Jan 9, 7:53 AM ESTWeekly Buzz: ScinoPharm Gets FDA Nod; GNLX's Olvi-Vec Shows Promise; GLUE's MRT-8102 Advances(RTTNews) – The biotech industry witnessed several key clinical trial data readouts across multiple therapeutic areas, including lung cancer, cardiovascular risk, Alzheimer's, and hepatitis.
- RTTNews · Jan 8, 2:14 PM ESTAcrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data(RTTNews) – Acrivon Therapeutics, Inc. (ACRV) shares fell 28.71%, trading at $2.1044, down $0.8456, after the company reported updated Phase 2b clinical results for its lead candidate ACR-368 in endometrial cancer.
- RTTNews · Jan 8, 8:42 AM ESTAcrivon's ACR-368 Shows 52% Response Rate In Endometrial Cancer, Expands Trial To Europe(RTTNews) – Acrivon Therapeutics, Inc. (ACVR) has unveiled promising Phase 2b data for its lead candidate ACR-368, showing a 52% confirmed overall response rate (cORR) in patients with serous endometrial cancer who have received two or fewer prior treatments. In biomarker-positiv
- NASDAQ.com · Jan 8, 8:28 AM ESTPre-Market Most Active for Jan 8, 2026 : ACRV, TSLL, TQQQ, CNCK, VTYX, NVDA, STLA, RDW, BBAI, SHCO, SMR, ACHRThe NASDAQ 100 Pre-Market Indicator is down -4.3 to 25,649.6. The total Pre-Market volume is currently 92,696,465 shares traded.The following are the most active stocks for the pre-market session: Acrivon Therapeutics, Inc. (ACRV) is -0.06 at $2.89, with 23,307,591 shares traded
- RTTNews · Jan 7, 10:14 PM ESTAfter-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates(RTTNews) – Several biotechnology and healthcare companies posted notable gains in after-hours trading on Wednesday, driven by clinical updates, financial results, and upcoming industry presentations.
- Zacks · Jan 7, 9:40 AM ESTIs Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year?Here is how Humacyte, Inc. (HUMA) and Acrivon Therapeutics, Inc. (ACRV) have performed compared to their sector so far this year.
- RTTNews · Jan 7, 4:34 AM ESTAcrivon To Deliver Clinical Updates On ACR-368 And ACR-2316 Tomorrow; Stock Soars(RTTNews) – Acrivon Therapeutics, Inc. (ACRV) will present updated interim data from its registrational-intent Phase 2b study of ACR-368, alongside initial clinical findings for ACR-2316, during a webcast scheduled for January 8, 2026.
- Fintel · Nov 25, 7:02 AM ESTHC Wainwright & Co. Reiterates Acrivon Therapeutics (ACRV) Buy RecommendationFintel reports that on November 25, 2025, HC Wainwright & Co. reiterated coverage of Acrivon Therapeutics (NasdaqGM:ACRV) with a Buy recommendation. Analyst Price Forecast Suggests 382.63% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Acrivon Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.